Inspire Medical Systems, Inc. (NYSE:INSP) Shares Purchased by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP grew its holdings in Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) by 98.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 232,333 shares of the company's stock after acquiring an additional 115,024 shares during the period. Dimensional Fund Advisors LP owned about 0.78% of Inspire Medical Systems worth $43,069,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Tidal Investments LLC purchased a new position in Inspire Medical Systems in the third quarter valued at $320,000. Synovus Financial Corp increased its stake in shares of Inspire Medical Systems by 7.5% in the 3rd quarter. Synovus Financial Corp now owns 3,502 shares of the company's stock valued at $739,000 after purchasing an additional 244 shares in the last quarter. Principal Financial Group Inc. boosted its position in Inspire Medical Systems by 3,812.6% during the third quarter. Principal Financial Group Inc. now owns 141,089 shares of the company's stock worth $29,777,000 after purchasing an additional 137,483 shares in the last quarter. Diversified Trust Co grew its holdings in Inspire Medical Systems by 3.8% in the fourth quarter. Diversified Trust Co now owns 4,686 shares of the company's stock valued at $869,000 after purchasing an additional 173 shares during the period. Finally, Wealth Enhancement Advisory Services LLC grew its holdings in Inspire Medical Systems by 1.0% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 7,879 shares of the company's stock valued at $1,461,000 after purchasing an additional 79 shares during the period. Hedge funds and other institutional investors own 94.91% of the company's stock.

Insider Buying and Selling at Inspire Medical Systems

In other news, insider Randy Ban sold 25,584 shares of the business's stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $183.50, for a total value of $4,694,664.00. Following the completion of the transaction, the insider now directly owns 7,259 shares of the company's stock, valued at $1,332,026.50. The trade was a 77.90 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Shawn Mccormick sold 360 shares of Inspire Medical Systems stock in a transaction dated Friday, May 2nd. The stock was sold at an average price of $160.00, for a total transaction of $57,600.00. Following the sale, the director now owns 24,046 shares of the company's stock, valued at approximately $3,847,360. This trade represents a 1.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 26,527 shares of company stock valued at $4,851,660. 4.10% of the stock is owned by corporate insiders.

Inspire Medical Systems Price Performance

Shares of INSP stock traded down $5.01 during trading hours on Wednesday, hitting $156.87. The stock had a trading volume of 735,186 shares, compared to its average volume of 589,638. The firm has a market capitalization of $4.67 billion, a PE ratio of 90.68, a PEG ratio of 2.86 and a beta of 1.39. The stock's 50 day moving average is $159.46 and its 200 day moving average is $179.13. Inspire Medical Systems, Inc. has a twelve month low of $123.00 and a twelve month high of $256.11.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported $0.10 earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.33. The business had revenue of $201.32 million during the quarter, compared to the consensus estimate of $194.89 million. Inspire Medical Systems had a net margin of 6.67% and a return on equity of 8.19%. The business's quarterly revenue was up 22.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.34) earnings per share. As a group, equities analysts predict that Inspire Medical Systems, Inc. will post 2.16 earnings per share for the current year.

Analyst Ratings Changes

INSP has been the topic of a number of research analyst reports. Royal Bank of Canada dropped their price target on shares of Inspire Medical Systems from $260.00 to $215.00 and set an "outperform" rating on the stock in a research note on Tuesday, April 15th. JPMorgan Chase & Co. cut their target price on shares of Inspire Medical Systems from $235.00 to $195.00 and set an "overweight" rating for the company in a research note on Tuesday. Piper Sandler reduced their price target on shares of Inspire Medical Systems from $260.00 to $233.00 and set an "overweight" rating for the company in a research report on Monday, February 10th. Wells Fargo & Company lowered their price objective on Inspire Medical Systems from $195.00 to $174.00 and set an "equal weight" rating on the stock in a report on Tuesday. Finally, Morgan Stanley reduced their target price on Inspire Medical Systems from $220.00 to $200.00 and set an "overweight" rating for the company in a report on Tuesday. Three investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $211.91.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.